Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Teaneck, New Jersey Clinical Trials

A listing of Teaneck, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (17) clinical trials

A Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Combination With Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

This is a randomized (individuals assigned to study treatment by chance), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to compare ...

Phase

7.45 miles

Learn More »

Medical Cannabis During Chemoradiation for Head and Neck Cancer

The primary purpose of the study is to observe the adherence and health seeking behavior of patients with Head and Neck cancer (HNC) certified to obtain medically certified cannabis as part of their supportive care regimen undergoing treatment with definitive or adjuvant concurrent chemoradiation (CRT).

Phase N/A

7.45 miles

Learn More »

Do you have angry outbursts? Are you easily irritated? Do you have a “short fuse”? Those terms can be associated with a disorder called Intermittent Explosive Disorder (IED). You may qualify to participate in a research study that will gather information about the effects of an investigational medication on the ...

Phase

7.45 miles

Learn More »

A Study Evaluating ABI-H0731+ NUC vs NUC Alone for the Treatment of Viremic HBeAg-positive CHB Patients

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Phase

7.73 miles

Learn More »

Study to Evaluate Efficacy Safety and Tolerability of MT 7117 in Subjects With Erythropoietic Protoporphyria

This is a Phase II, randomized, double-blind, placebo controlled study to assess the efficacy, tolerability, and safety of MT-7117 in subjects with EPP. The study consists of a 2 week screening period, a 16 week double-blind treatment period, and a 6 week follow-up period at Week 22. The total participation ...

Phase

7.73 miles

Learn More »

A Study Evaluating ABI-H0731 as Adjunctive Therapy in HBeAg-positive Patients With Chronic Hepatitis B

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed HBeAg-positive Patients with Chronic Hepatitis B

Phase

7.73 miles

Learn More »

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

This is an open label, non-randomized Phase I study of intravenous avelumab every 2 weeks to be administered after real-time MRI-guided LITT therapy for patients with a first recurrence of a glioblastoma. The primary objective of the study is to characterize the tolerability and safety profile of avelumab in combination ...

Phase

7.73 miles

Learn More »

Obesity and Caries in Young South Asian Children: A Common Risk Factor Approach

CHALO builds upon the team's prior research re: cariogenic (R34-DE-022282) and obesogenic behaviors (10, 14, 15). CHALO's intervention components-- home visits, phone support, and "patient navigation" to dental visits-- proved to be feasible and acceptable. In the pilot R34, there were promising behavioral change on all measures. CHALO builds on ...

Phase N/A

8.59 miles

Learn More »

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with nivolumab (Part 2).

Phase

9.09 miles

Learn More »

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

This study will determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors who have progressed on standard of care ...

Phase

9.09 miles

Learn More »